Objective
Cancer represents a critical public health issue, with 2.74 million new cases diagnosed in Europe in 2022. Most cancer-related deaths are attributed to metastatic spread and it is estimated that 20-40% of all cancer patients will develop metastases to the brain (BrM), facing a dismal prognosis. Novel immunotherapies have shown promising outcomes in BrM patients, although a substantial proportion remain unresponsive. This reflects the heterogeneous nature of the tumor immune microenvironment (TIME) and emphasizes the need for a better understanding of its role driving pro- or anti-tumoral responses. My postdoctoral research suggested an important role for genetic variation in human BrM cancer cells regulating the composition and function of the TIME. Likewise, ageing has a major impact in the ability of the immune system to fight cancer. However, how these two key factors interact and influence responses to therapy remains unknown.
IMMUNAGENOMICS aims to transform personalized care for BrM patients by offering a multidisciplinary view on the dynamic regulation of the TIME by ageing and genetic variation. Specifically, we will: (i) characterize changes in baseline immunity along ageing;(ii) evaluate responses to radio- and immunotherapy in young and aged mouse models of BrM bearing different somatic mutations; (iii) analyze the TIME of BrM tumors from young and aged mice, pre and post-treatment by complementary orthogonal approaches including: flow cytometry, hyperplexed immunofluorescence imaging, scRNA-Seq and spatial transcriptomics; (iv) examine the link between ageing, genetic variation, TIME phenotypes and responses to therapy in collections of banked human BrM samples.
Overall, I envision that IMMUNAGENOMICS will help decipher the complex interplay between ageing and genomic variation shaping immune responses against BrM tumors, ultimately opening new perspectives for the development of more effective personalized therapies for this devastating form of cancer
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics mutation
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.1.1 - European Research Council (ERC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-ERC - HORIZON ERC Grants
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) ERC-2025-STG
See all projects funded under this callHost institution
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1445 Strassen
Luxembourg
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.